Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB3101 SAD in Healthy Participants
NCT06555601Phase 1Terminated
- Sponsor
- UCB
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UCB3101 (8 cohorts), sponsored by UCB. Primary endpoint: Incidence of any treatment-emergent adverse events. Started Jul 2024; status: terminated.
02
Drugs
UCB3101
Beyond the preview
Go deeper on NCT06555601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555601.